Mosunetuzumab

Unassigned

New Medicines

Relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) - third-line or greater

Information

New molecular entity
Roche
Roche

Development and Regulatory status

Phase I Clinical Trials
Phase I Clinical Trials
Phase II Clinical Trials

Category

A T-cell-recruiting bispecific antibody targeting CD20-expressing B cells
The two most common types of NHL are DLBCL and follicular lymphomas. The overall annual incidence of DLBCL in Europe is 3.8/100,000 but the incidence increases with age and varies considerably across Europe. The annual incidence of follicular lymphomas has increased from 2-3/100,000 during the 1950s to 5-7/100,000 recently [1].
Relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) - third-line or greater
Intravenous infusion